

March 6, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”):

Pursuant to Regulation 30 of SEBI Listing Regulations, we hereby inform that one of the subsidiary of the Company i.e., Optival Health Solutions Private Limited has received a suspension order from Drugs and Control authorities, under Drugs and Cosmetic Act, 1940 read with rules made thereunder for temporarily suspending the operations of store as mentioned in the table given below. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details are provided below:

Name(s) of the Authority:	Nature and details of the action(s) taken, initiated or order(s) passed.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Details of the violation(s) / contravention(s) committed or alleged to be committed	Impact on financial operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible
Assistant Director, Drugs Control Administration, Chennai, Kanchipuram Zone	Temporary suspension of Drug License for 5 days a store situated at Haridossapuram, Chennai.	Order received on 05.03.2024	Under Section 18(c) Rule 65(2), 65(3)(i), 65(4)(3)(i) of Drugs and Cosmetics Act, 1940 read with Drugs and Cosmetics Rules, 1945.	Potential Revenue Loss of Rs~ 0.65 Lacs.

The Company is reviewing the aforesaid order and evaluating the next steps in this matter.
Kindly take the same on records.

For MedPlus Health Services Limited

Manoj Kumar Srivastava
Company Secretary
FCS 7460